## Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

## M. 10255 - TRITON / BERGMAN CLINICS

## SECTION 1.2

## Description of the concentration

The notified concentration relates to the proposed indirect acquisition of sole control within the meaning of Article 3(1)(b) of the EU Merger Regulation of Bergman Healthcare Clinics B.V. ("Bergman Clinics", Netherlands) by the Triton group ("Triton", Jersey) by way of a purchase of shares.

The investment funds managed and advised by Triton invest primarily in medium-sized businesses headquartered in Central and Northern Europe, with a particular focus on businesses in four core sectors: Business Services, Industrials, Consumer, and Health. One of Triton's portfolio companies, Aleris Group AB, established in Stockholm, Sweden, is active in the provision of ophthalmological services in both Sweden and Norway.

Bergman Clinics operates clinics throughout the Netherlands, Sweden, Denmark, Norway, and Germany which offer high quality, plannable medical care in the field of orthopaedics, ophthalmology, gynaecology, aesthetic medicine, cardiology, gastroenterology, dermatology, and vascular medicine. One of Bergman Clinics' portfolio companies, Memira AB, established in Solna, Sweden, is active in the provision of ophthalmological services across the Nordic countries.

